Drug recall · February 21, 2018
Limbrel recall
Why: Marketed Without An Approved NDA/ANDA: Based on the labeling claims, these products are unapproved drugs for which the safety and efficacy have not been established and, therefore, subject to recall.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Limbrel (flavocoxid 250 mg) capsules, 60-count bottle, Rx only, Manufactured for: Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253; Manufactured by: Cornerstone Research and Development, Ogden, UT 84404, NDC 68040-601-16.
- Lots / codes
All lots within expiry.
- Quantity
- 7,826 bottles
- Company
- Primus Pharmaceuticals, Inc., Scottsdale, AZ
- Distribution
- Nationwide in the USA.
- Initiated
- January 26, 2018 · Voluntary: Firm initiated
- Classified
- February 9, 2018
- Reported
- February 21, 2018
- Ended
- July 16, 2019
- How notified
- Press Release
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.